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ABSTRACT
The purpose was to evaluate 2 intramammary treat-
ments for mild-to-moderate cases of clinical mastitis 
in a noninferiority comparison. Noninferiority trials are 
intended to show whether a given treatment, hetacillin 
potassium, has at least comparable efficacy as the ref-
erence treatment, ceftiofur hydrochloride. Treatments 
can be deemed inferior to the reference treatment by 
an amount less than the margin of noninferiority, or 
inconclusive if the confidence interval crosses the mar-
gin of noninferiority. Cows with clinical mastitis from 6 
farms were considered for enrollment. Using a random-
ized design, cows with mild or moderate mastitis in 1 
quarter were assigned to on-label treatment with either 
ceftiofur or hetacillin. A total of 596 cows met the 
criteria needed for continued enrollment. Treatment 
distribution resulted in 309 cows in the ceftiofur group 
and 287 cows in the hetacillin group. Mixed regression 
analysis was performed for the following outcomes: bac-
teriological cure, pathogen cure, clinical cure, postevent 
milk production and linear score, and survival to d 30 
and 60. Cox proportional hazards analysis was used to 
describe treatment effect on survival and mastitis risks. 
Bacteriological cure, defined as absence of causative or-
ganism in samples retrieved at d 14 and 21 postmastitis, 
was similar between groups. No significant statistical 
differences were found in cure risk, and noninferiority 
of hetacillin relative to ceftiofur for bacteriological cure 
was conclusive (hetacillin = 67%, ceftiofur = 72%). 
Absence of a pathogen on both follow-up samples des-
ignated a cow as a pathogen cure. Pathogen cure was 
similar between treatment groups and noninferiority of 
hetacillin relative to ceftiofur was shown (hetacillin = 
35%, ceftiofur = 32%). Clinical cure (hetacillin = 68%, 
ceftiofur = 64%), postevent milk production (hetacillin 
= 37.0 kg, ceftiofur = 38.2 kg), and linear scores (het-
acillin = 3.4, ceftiofur = 3.1) were also not statistically 
different between treatment groups. Noninferiority of 
hetacillin relative to ceftiofur was shown for survival 
to d 30 and survival to d 60, whereas hetacillin was 
more likely to have a clinical cure than ceftiofur by d 
4. No differences were seen between groups when Cox 
proportional hazards were performed, neither for exit 
from the herd in the 60 d following the event nor in the 
risk for a subsequent mastitis event. These findings can 
be used to develop farm-specific protocols for clinical 
mastitis treatment.
Key words: clinical mastitis, hetacillin, noninferiority, 
ceftiofur
INTRODUCTION
The antimicrobial treatment options available to 
dairy producers for clinical mastitis (CM) are required 
by United States agencies to exhibit efficacy relative 
to a nontreated negative control. Very few studies have 
rigorously compared available treatments to positive 
controls using appropriate on-farm trials. It would be of 
benefit to perform controlled trials comparing 2 exist-
ing treatments.
In the United States, only 2 classes of antimicrobials 
are commercially available for intramammary (IMM) 
treatment of CM: β-lactams and lincosamides (Baynes 
and Riviere, 2014). In this study, we compared 2 
β-lactams. Hetacillin potassium (Hetacin K, Boehringer 
Ingelheim, St. Joseph, MO) is a broad-spectrum IMM 
antibiotic approved to treat gram-negative and -posi-
tive mastitis-causing pathogens such as Streptococcus 
agalactiae, Streptococcus dysgalactiae, Staphylococcus 
aureus, and Escherichia coli (FDA, 2010). Hetacillin 
is chemically related to ampicillin and was shown to 
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maintain necessary MIC in a 3 times-per-day milking 
regimen (Lindquist et al., 2015). Ceftiofur hydrochloride 
(Spectramast LC, Zoetis, Kalamazoo, MI) is a broad-
spectrum third-generation cephalosporin indicated to 
treat mastitis associated with CNS, Strep. dysgalactiae, 
and E. coli (FDA, 2005). Whereas both drugs have 
an established milk withdrawal time of 72 h, average 
length of recommended treatment varies. The label 
indication for ceftiofur is administration every 24 h for 
2 to 8 d, but the hetacillin label states a 3-d duration 
at the same daily interval. The average duration for 
the use of ceftiofur for mild, moderate, and severe CM 
was 4.0, 4.4, and 4.5 d in a recent Wisconsin survey, 
respectively (Oliveira and Ruegg, 2014).
A 2-sided comparative study must prove a higher 
defined efficacy for the proposed treatment over the 
current standard-of-care treatment in a clinical setting 
with the purpose to reject the null hypothesis that the 
therapies are not different; if the evidence is not strong 
enough to favor the tested product, the researcher can-
not rule out nor conclude equality. Noninferiority of a 
therapy is established when the data provide evidence 
to conclude that its efficacy is within a certain amount 
of the equivalence margin of the comparison therapy 
(Walker and Nowacki, 2011). If a researcher can hy-
pothesize and confirm that a therapy is equivalent or 
superior to the reference, benefits to the patients can 
include convenience, lower costs, fewer side effects, 
improved delivery systems, and better integration into 
a current protocol (Piaggio et al., 2006; Walker and 
Nowacki, 2011).
With regard to mastitis research, 3 major studies 
involving Food and Drug Administration-approved 
IMM preparations have been previously performed as 
noninferiority trials. Schukken et al. (2013) concluded 
noninferiority between a first-generation cephalosporin 
and a third-generation cephalosporin when considering 
both clinical cure of all nonsevere CM cases and bac-
teriological cure of gram-positive cases. Their specific 
interest was to determine any difference in efficacy 
given that first-generation cephalosporin have lim-
ited gram-negative activity whereas third-generation 
products have broader activity claims (Hornish and 
Kotarski, 2002; Guerín-Faublee et al., 2003; Pfeifer et 
al., 2010). The second and third noninferiority trials 
performed by Arruda et al. (2013) and Johnson et al. 
(2016) on dry-cow therapy treatments determined non-
inferiority when considering various indexes, including 
postcalving new infection risk. No similar comparison 
has been made between a third-generation cephalospo-
rin, ceftiofur, and a semisynthetic penicillin, hetacillin, 
in the treatment of mild to moderate CM. A Northeast 
survey study comparing bacteriological cure rates for 7 
mastitis drugs was performed by Wilson et al. (1999). 
Whereas cure rates for cephapirin rather than ceftiofur 
were analyzed, hetacillin cure rate was comparable to 
the cephalosporin product (62%, n = 35/56 vs. 68%, 
n = 152/222, respectively). However, given its compa-
rable cure rate, a 2014 study on 51 large dairy herds 
in Wisconsin indicated that only 3.3% (n = 21/645) of 
CM cases were treated with IMM hetacillin, whereas 
71.6% (n = 462/645) of cases were treated with ceftio-
fur (Oliveira and Ruegg, 2014).
The current study compared the treatment efficacy 
of a 3-d administration of IMM hetacillin to a 5-d ad-
ministration of the reference treatment ceftiofur. The 
objective of our trial was to evaluate whether noninfe-




This was a randomized noninferiority study. The con-
cept of a noninferiority trial is formalized in the term 
equivalence margin, which defines a range of values 
for which the efficacies or margins between differences 
in clinical outcome are close enough to be considered 
equivalent (Walker and Nowacki, 2011). A prestated 
margin of noninferiority is chosen as the smallest value 
that would show a clinically important effect. This 
margin is also used in a statement of hypothesis; in 
our study, the null hypothesis was that a 3-d treatment 
with hetacillin is inferior compared with an extended 
5-d treatment with ceftiofur when considering bacte-
riological cure, clinical cure, pathogen cure, and sur-
vival indices. The alternative hypothesis was that a 3-d 
treatment with hetacillin is noninferior compared with 
an extended treatment with ceftiofur by more than the 
equivalence margin of 15%. The choice of equivalence 
margins is often less than half of the expected effect in 
a traditional study. In a trial comparing treatment of 
gram-negative CM cows, bacteriological cure was ~35% 
greater for cows treated with ceftiofur than for cows 
receiving no treatment (ceftiofur n = 41/56; control n 
= 18/48; Schukken et al., 2011). Additional assessment 
of differences in postevent milk production, postevent 
linear score, and days in the treatment pen (hospital 
days) was evaluated using traditional hypotheses rather 
than noninferiority comparisons.
Study Farms
This trial was conducted between September 2014 
and June 2015 at 6 commercial dairy farms in major 
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dairy-producing regions of New York State. Farms 
eligible for inclusion in the study met the following 
criteria: herd size >500 lactating cows; participation 
in monthly DHIA testing; accurate recording of CM 
cases; and willingness to participate and follow stan-
dard operating procedures, which included not waver-
ing from treatment plans for 7 d. A known presence of 
streptococcal CM was also required to ensure appropri-
ate representation of gram-positive and gram-negative 
etiologies. Medians for this sample of herds were 1,057 
lactating cows (range: 524 to 1466), 12,150 kg/cow 
per year of milk (range: 11,773 to 13,091 kg), and a 
bulk tank SCC of 140,500 cells/mL (range: 100,000 to 
267,000 cells/mL).
Case Definition
All cases of CM at each of the 6 Holstein dairies were 
assessed for enrollment at the time of occurrence. A 
cow was defined as having CM if milk was abnormal 
from one or more quarters. A clinical scoring system 
(CS) adapted from Wenz et al. (2001) was used to 
classify CM cases based on severity, and only cows with 
CS of 1 or 2 were included. Severity of clinical signs 
was scored as mild (CS = 1), moderate (CS = 2), or 
severe (CS = 3). A score of 1 was assigned if the milk 
was visually abnormal; a score of 2 was assigned if the 
milk was visually abnormal and firmness or swelling of 
the affected quarter was observed; and a score of 3 was 
assigned if the milk was grossly abnormal, firmness or 
swelling of the affected quarter was observed, and signs 
of systemic disease were present (e.g., fever, dehydra-
tion, or depression).
In addition to a CS <3, a cow needed to meet the 
following criteria: less than 300 DIM, neither CM nor 
antimicrobial administration in the last 30 d, parity 
<6, only 1 quarter exhibiting signs of CM, and no pre-
vious enrollment in the trial.
Treatment Groups
At each farm location, lactating cows with CM that 
met the inclusion criteria were randomly allocated to 
one treatment group via Dairy Comp 305 (DC305, 
Tulare, CA; 4 farms) or via randomized envelopes 
containing treatment assignment (2 farms). Treatment 
groups included a test treatment group consisting of 
cows receiving 1 treatment of hetacillin once per day 
for 3 d into the affected quarter and a reference treat-
ment group consisting of cows receiving 1 treatment of 
ceftiofur once per day for 5 d into the affected quarter. 
Intramammary treatments were administered using 
partial insertion technique by trained farm personnel.
Timing of Events
The day of enrollment, also the first day of treatment, 
was defined as d 1 and commenced upon randomized al-
location of treatment group. Before treating a cow, the 
teat of the affected quarter was thoroughly disinfected 
and 3 streams of milk from the affected quarter were 
discarded. A milk sample was taken using aseptic tech-
nique and immediately placed in the on-farm freezer. 
After the sample was taken, the teat end was disin-
fected again and treated with the allocated treatment. 
The cow was marked as treated using a leg band, per 
standard on-farm protocol. For each treatment, a dated 
and signed treatment confirmation was completed. A 
CS for cows in both groups was also obtained on d 2 to 
5 following the initial score on d 1. Approximately 14 d 
(±4 d) and 21 d (±5 d) after the onset of treatment, a 
milk sample was collected from the enrolled quarter and 
a CS was determined. Resamples were obtained at least 
7 d apart for each cow. If at any time an animal became 
systemically ill following randomization and treatment, 
farm personnel was advised to remove the animal from 
the study and initiate additional treatments. In these 
cases, a milk sample and CS were collected before ad-
ditional treatments were provided. If a cow sustained 
mastitis in another quarter, it was removed from the 
trial with the same requirements.
Bacteriological Culture
Standard culture technique was performed on all 
samples according to National Mastitis Council guide-
lines for identification of aerobic organisms (National 
Mastitis Council, 1999). Briefly, 0.01 mL of milk was 
streaked on trypticase soy agar containing 5% sheep 
blood and 1% esculin (PML Microbiologicals, Mis-
sissauga, ON, Canada), and plates were incubated 
aerobically at 37°C for 18 to 24 h. After observations 
of colony morphology and hemolytic patterns, isolates 
were examined further by means of 3% potassium hy-
droxide, Gram staining, catalase and indole testing, 
and additional biochemical and metabolic evaluations 
as needed. Gram-negative organisms were identified by 
colony morphology on MacConkey’s agar (Hardy Diag-
nostics, Santa Maria, CA). Diagnosis and confirmation 
of IMM infection by culture was based on standard 
published definitions and assessed at the quarter level. 
Briefly, an IMM infection was defined as 1 or more 
colonies isolated from the 10-μL milk sample for all 
pathogens except for CNS. For CNS, 2 or more colonies 
isolated from the 10-μL milk sample were needed to 
establish presence of an infection (Dohoo et al., 2011). 
When 2 different types of bacteria were identified, the 
result was classified as a mixed infection. When at least 
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1 colony each of 3 or more of types was isolated, the 
sample was considered contaminated.
Data Capture
Sampling and clinical data collection was performed 
by farm staff (5 farms) or a support technician (1 
farm). Farm staff was trained by Quality Milk Produc-
tion Services (Ithaca, NY) personnel and veterinarians 
to identify mastitis, assign severity scores, enroll cases, 
collect samples, and complete paper records. Qual-
ity assurance audits were performed by Quality Milk 
Production Services and herd veterinarians and regular 
visits were performed by the first author.
Sample Size Determination
The required sample size was determined using the 
confidence interval approach, considering where the 
confidence interval for the treatment effect lies with 
respect to both the margin of noninferiority (Δ), and a 
null effect (treatments are equal). Sample size depends 
on the level of confidence chosen, the risk of Type II 
error (or desired power), and Δ. Here we specified Δ 
as the difference in cure risk ratios between the 2 treat-
ments. A binomial distribution was performed assum-
ing a ceftiofur cure risk of 65% based on a randomized 
clinical efficacy trial (Schukken et al., 2011), plotting 
Δ as the independent variable and power and sample 
size as dependent variables. This was used to find the 
sample size (n = 250 per group) with a chosen value 
for power (0.9) and a chosen value of Δ (0.15), which 
is less than half of the expected effect of ceftiofur in a 
traditional clinical trial (Schukken et al., 2011). The 
total study size is then twice this number, or 500. We 
enrolled 600 cows to ensure adequate study power while 
accounting for loss to follow-up and a Type I error risk 
of 5%.
Primary and Secondary Outcomes
Primary outcomes were bacteriological cure, clinical 
cure, and pathogen cure. A quarter was defined as a 
bacteriological cure when there was a pathogen pres-
ent in the pretreatment sample and this pathogen was 
absent from both posttreatment samples (d 14 and 21). 
Cows that initially cultured with no growth or contami-
nation were not included in analysis for bacteriologi-
cal cure. If one of the follow-up samples contained the 
same organism as the pretreatment sample, the quarter 
was defined as a noncure. If a cow left the trial due 
to mastitis reasons and her exit sample revealed the 
same organism as the pretreatment sample, the quar-
ter was defined as a noncure. If none of the present 
samples cultured with the enrollment organism, but a 
cow was missing one or both follow-up samples or a 
removal sample, the cow was deemed lost to follow-up 
for bacteriological cure. If none of the present samples 
cultured with the enrollment organism and one of the 
samples was contaminated, the cow was also lost to 
follow-up for this outcome. Samples were missed due to 
treatment for other ailments, input error, or early dry 
or sale. If no exit sample was present before the 21-d 
sample collection period, the cow was lost to follow-up 
for bacteriological cure. Differences in frequencies of 
lost to follow-up between treatment groups were noted 
for each outcome.
A quarter was defined as a clinical cure within the 
first 5 d and for the follow-up records when its CS 
became and remained zero. Clinical cure was dichoto-
mized to include 2 groups: those cows that cured by d 
4 and those that did not. Day 1 to 5 trial records were 
considered sufficient to determine clinical cure.
When both follow-up samples contained no growth, 
the cow was defined as a pathogen cure. A pathogen 
did not need to be present in the pretreatment sample 
to be defined as a pathogen cure. Cows with contami-
nated samples were lost to follow-up and not considered 
for pathogen cure analysis. If a cow had 1 of 2 follow-
up samples with no growth but was missing a second 
sample, the cow was also lost to follow-up.
Secondary outcomes were extended clinical cure, 
number of clinical days, posttreatment milk production 
and linear score, survival of the cow in the herd, occur-
rence of another mastitis event in the same quarter, and 
hospital days. A quarter was defined as an extended 
clinical cure when its CS was 0 on d 14 and 21 after 
the event. The clinical days outcome was defined as the 
time to clinical cure and was calculated as the number 
of days from entrance into the treatment pen until clini-
cal signs were undetectable. Hospital days were defined 
as the number of days (in 24-h intervals), between en-
trance dates and exit dates into or from the treatment 
pen. Previous milk production and linear scores (LS) 
were obtained from the test day data before the event 
(range: −8 d to −43 d pre-event). Postevent milk pro-
duction and LS were obtained from the test day after 
the event (range: 8 to 43 d postevent). Linear score is 
a transformation of SCC, calculated as [Ln(SCC/100)/
Ln(2)] + 3 (Ali and Shook, 1980). Survival analysis 
was evaluated by following the cow to dry, cull, or 60 d 
postenrollment, whichever came first.
Statistical Analysis
Noninferiority analysis of binary outcomes was com-
pleted using PROC FREQ in SAS version 9.4 (SAS In-
stitute, 2014) with one-sided 95% confidence intervals 
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and noninferiority margins. Statistical analysis of the 
primary and secondary outcomes was performed using 
regression models, taking into account the following 
covariates: parity, DIM, hospital days, previous milk 
yield, LS, and CM etiology. To select the best model, all 
possible confounding variables were subjected to bivari-
ate analysis by means of Chi-squared, t-tests, or ANO-
VA tests using PROC FREQ, PROC TTEST, PROC 
REG, or PROC ANOVA. The primary explanatory 
variable of interest was treatment group; all interac-
tions with this variable were tested in a similar manner. 
Any terms with a P-value <0.2 were offered into the 
models. Each variable was then examined by manual 
backward stepwise elimination in the regression until 
all possible explanatory variables with P < 0.1 were 
included. In many of the models, the treatment vari-
able was forced. Farm was first tested as a fixed effect 
and, if determined not to be significant to the level of 
P < 0.10, it was then included as a random effect. This 
corrected for any within-farm clustering that violated 
the assumptions of independence. Additionally, basic 
techniques were used to assess normality, homoscedas-
ticity, and linearity of variables. Transformations were 
performed and reported as necessary. Not all included 
animals had complete LS or milk yield data, as some 
cows experienced the event in early lactation with no 
prior test day or late in lactation with no post-CM test 
day. Cows were excluded from hospital days or clinical 
days analyses if pen moves were not complete in DC305 
records. Where analyses were performed on a subgroup 
of animals, the number of animals with complete data 
is indicated in the tables.
Mixed logistic regression models were performed 
for the binary outcomes bacteriological cure, patho-
gen cure, clinical cure by d 4, survival to d 30, and 
survival to d 60. Mixed linear regression models were 
performed for postevent milk yield and postevent LS. 
Time in the herd from d 0 to 60 postevent was evalu-
ated using Cox proportional hazards regression (PROC 
PHREG). Similar analysis was performed to describe 
the effect of treatment on the survival distribution of 




Enrollment characteristics for each of the 6 farms are 
shown in Table 1. In total, the farms experienced 1,168 
cases of mastitis, 161 of which were severe (13.8%). The 
number of mastitic cows meeting eligibility criteria was 
627. Thirty-one cows did not remain in the study due 
to secondary treatment of the quarter or cow within 
the first 7 d of enrollment (n = 15; hetacillin = 12, 
ceftiofur = 3), mastitis in another quarter within 7 d 
(n = 8; hetacillin = 4, ceftiofur = 4), nonsurvival of 
cow or quarter (n = 7; hetacillin = 3, ceftiofur = 4), 
and input errors (n = 1, ceftiofur). The mean time of 
first follow-up sample was 14.1 d postevent (±1.9 d; 
SD) and second follow-up sample was 21.2 d postevent 
(±2.2 d). Eight cows did not have enrollment samples, 
but could be assessed for the following outcomes: clini-
cal days, hospital days, postevent milk production and 
LS, and survival indices. Of the cultures, 63% produced 
diagnostic growth (n = 369/588), 31% resulted in no 
organism (n = 183/588), and the remaining 6% re-
sulted in no significant growth or contamination (n = 
36/588). Of all etiologies, the most frequently cultured 
gram-positive organisms found were Strep. dysgalactiae 
(14.0%; n = 84/588) followed by Staph. aureus (8.0%; n 
= 47/588) and Streptococcus uberis (7.8%; n = 46/588). 
Escherichia coli (13.8%; n = 81/588) was the most 
commonly isolated gram-negative organism, followed 
by Klebsiella spp. (5.4%; n = 32/588) and Pasteurella 
spp. (1.0%; n = 6/588). All etiologies were evenly dis-
tributed (P > 0.05) except for Strep. uberis, for which 
72% (n = 33/46) of cases were randomly allocated to 
the ceftiofur group whereas 28% (n = 13/46) were al-
located to the hetacillin group (P < 0.01). Distribution 
of organisms within each treatment group can be seen 
in Table 2.
The distribution of treatments was nearly equivalent; 
48% of cows were assigned to the hetacillin group (n = 
287/596) and 52% of cows were assigned to the ceftiofur 
group (n = 309/596). Distribution of treatment group 
by farm was also not statistically different (P = 0.68). 
We found no statistical differences in the means of 
DIM (hetacillin = 130 d, ceftiofur = 129 d; P = 0.78), 
lactation number (hetacillin and ceftiofur = 2.7; P = 
0.46), previous test-day LS (hetacillin = 2.3, ceftiofur 
= 2.5; P = 0.37), and milk yields (hetacillin = 42.5 kg, 
ceftiofur = 42.7 kg; P = 0.80). The quarter affected did 
not differ between groups (P = 0.70).
Bacteriological Cure
Cases were not eligible for bacteriological cure when 
the treated quarter had no growth (n = 183) or con-
taminated growth (n = 25) on initial culture. If a case 
did not meet the appropriate collection times for follow-
up samples, it was not included in analysis (n = 1). If 
a cow had any of the criteria defined in Materials and 
Methods as lost to follow-up, the cow was not included 
in analysis (n = 35). The number of cases meeting in-
clusion criteria was 353: 164 hetacillin-treated cows and 
189 ceftiofur-treated cows had complete data. Bacterio-
logical cure was seen in 250 cases (71%): 112 (68%) of 
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the hetacillin cows and 138 (73%) of the ceftiofur cows. 
Differences in bacteriological cure percentages based on 
etiology and treatment group can be seen in Figures 1 
and 2.
When stratified by Gram stain classification, 74 of 
106 (70%) ceftiofur-treated cows with gram-positive 
mastitis cured whereas 57 of 90 (63%) of hetacillin cows 
with gram-positive cultures experienced bacteriological 
cure. Of the cows with gram-negative mastitis, 82% of 
the ceftiofur group cured (n = 49/60) whereas a similar 
percentage (79%) of the hetacillin group cured (n = 
42/53).
Mixed model logistic regression of bacteriological cure 
produced a model that included etiology and treatment 
group as explanatory variables (Table 3). Interactions 
between treatment group and etiology were assessed, 
but any observed interactions were likely due to chance 
assuming the null hypothesis was true. When control-
ling for treatment, odds of bacteriological cure for all 
CM organisms, except for Staph. aureus, were higher 
than the grouping of other organisms that included 
Pseudomonas, yeast, Prototheca, Corynebacterium, and 
Enterococcus. These increased odds were statistically 
significant for E. coli and Strep. dysgalactiae. The odds 
ratio (OR) for bacteriological cure between treatment 
groups was approximately 1.3 times higher for ceftio-
fur-treated cows compared with hetacillin-treated cows 
(95% CI: 0.77–2.1, P = 0.32). Least squares means for 
bacteriological cure for hetacillin-treated cows was 67% 
(95% CI: 59–75%), whereas it was 72% for ceftiofur-
treated cows (95% CI: 65–79%).
Calculation of point estimates for cure risk differ-
ences can be seen in Figure 3. The risk difference be-
tween the groups was −0.047, with a 95% confidence 
interval of −0.14 to 0.048. When stratified by Gram 
staining classification (n = 309; gram-positives n = 
196, gram-negatives n = 113), a larger risk difference 
was seen in the gram-positive organisms (−0.065; 95% 
CI: −0.197–0.068). The risk difference was least nega-
tive for gram-negative etiologies at −0.024 (95% CI: 
−0.171–0.122).
Clinical Cure
A total of 572 cows met the criteria necessary to 
assess this outcome (hetacillin = 268, ceftiofur = 304). 
Of the initial 596 cows, 24 cows did not have scores re-
corded for the required 5 sequential days and were not 
included in analysis. Overall, 64% of cows experienced 
≤4 clinical days (n = 366/572). Of the hetacillin-treated 
cows, 70% experienced ≤4 clinical days (n = 187/268) 
whereas 59% of ceftiofur-treated cows experienced ≤4 
Table 1. Basic description (numbers) of clinical mastitis (CM) cases and enrolled cases on 6 commercial dairy 
farms (A–F) in New York during the trial period
Item A B C D E F Total
Total CM cases 110 335 138 198 168 219 1,168
Total nonsevere CM cases 94 226 132 183 161 211 1,007
Number meeting eligibility criteria 74 130 84 105 129 105 627
Number of cases maintaining enrollment 71 119 78 99 125 104 596
Hetacillin 28 55 40 50 62 52 287
Ceftiofur 43 64 38 49 63 52 309
Culture results (pretreatment)        
 No growth 30 53 11 18 40 31 183
 Gram-positive 17 29 48 44 43 41 222
 Gram-negative 8 17 8 35 29 16 113
 Other1 16 20 11 2 13 16 78
1Culture results falling into this category are defined in Table 2.







No growth 95 88
No significant growth1 17 11
Escherichia coli 36 45
Klebsiella spp. 17 15
Streptococcus dysgalactiae 47 37
Streptococcus uberis 13 33
CNS 5 6
Staphylococcus aureus 21 26
Other cocci2 20 26
Other Enterobacteriaceae 6 2
Other organisms 21 29
Pseudomonas spp.1 0 1
Pastuerella 1 5
Proteus spp. 0 1
Yeast1 4 8
Prototheca spp.1 1 0
Trueperella pyogenes1 3 5
Gram-positive bacillus 1 1
Contamination1 0 2
Missing sample1 5 3
1Included in other category of Table 1.
2Includes non-Strep. uberis/non-Strep. dysgalactiae, Streptococcus spp., 
Enterococcus spp., and Lactococcus spp.
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clinical days (n = 179/304; P = 0.007). A noninferiority 
analysis calculated a proportion difference of 0.12 (95% 
CI: 0.031–0.19; Figure 3.).
A mixed binomial logistic regression model includ-
ing treatment group and log of hospital days resulted 
in similar least squares means of clinical cure for each 
group (68% for hetacillin, 64% for ceftiofur). A total 
of 352 cows with full data were included in regression 
analysis. The effects of treatment group were not sta-
tistically significant in the model (P = 0.65). When 
hospital days were included, the odds ratio of having 
≤4 clinical days for hetacillin-treated cows versus 
ceftiofur-treated cows, although higher (1.2), was not 
significantly different from 1 (95% CI: 0.62–2.2; P = 
0.57). As interpreted, an increase in hospital days leads 
to a decrease in the log-odds for the outcome of clinical 
days ≤4.
Pathogen Cure
Absence of a pathogen on both follow-up samples 
designated a cow as a pathogen cure. To be considered 
a pathogen cure, both follow-up samples as well as the 
enrollment sample had to be present and not contami-
nated (missing, n = 23; contaminated, n = 39). If a 
cow had any of the criteria defined in Materials and 
Methods as lost to follow-up, it was not included in 
analysis (n = 11). If a case did not meet the appropri-
ate collection times for follow-up samples, the case was 
not included in analysis (n = 2). A total of 521 cows 
were used in the analysis (ceftiofur = 271, hetacillin = 
250) and 462 cows had full data for modeling. A cow 
with a no growth or growth result upon enrollment had 
to maintain a no growth result in both of its follow-up 
samples to be considered a pathogen cure. Overall, 44% 
of cows experienced a pathogen cure: 45% of hetacillin-
treated cows and 43% of ceftiofur-treated cows. Mixed 
model logistic regression resulted in a numerically better 
pathogen cure (OR = 1.1) for hetacillin-treated cases 
as compared with the ceftiofur cases, but the observed 
difference was likely due to chance (P = 0.57). Least 
squares means for hetacillin-treated cows was 35% in 
the model whereas 32% cured for ceftiofur (95% CI: 
hetacillin = 22–50%; ceftiofur = 20–47%). Variables 
significant in the model were etiology, previous LS, and 
previous milk yield (Table 4).
No growth results were exempt from the analysis de-
scribed by Table 3. However, the effects of this etiology 
were reflected in the logistic model for pathogen cure: 
when all other variables were held constant, odds of 
Figure 1. Bacteriological (Bact.) and clinical (Clin.) cure percentages for the following mastitis etiologies on aerobic culture: Staphylococcus 
aureus, Streptococcus dysgalactiae, Streptococcus uberis, and other streptococcal organisms. Error bars indicate 95% CI based on SE of the mean 
proportion.
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pathogen cure for all etiologies except for E. coli were 
trending lower or significantly lower than no growth 
results, indicating that cows experiencing a no growth 
result were likely to remain no growth at both resample 
dates. Whereas E. coli CM had an increased odds of 
pathogen cure, it was not statistically significant (P = 
0.93). Interactions between treatment group and etiol-
ogy were assessed but not statistically significant to the 
level of P < 0.05. As milk yield or LS increased, the 
odds of pathogen cure decreased.
Point estimates for pathogen cure risk differences 
with confidence intervals can be seen in Figure 3. The 
risk difference between the groups was 0.020, with a 
95% confidence interval of −0.065 to 0.11.
Figure 2. Bacteriological (Bact.) and clinical (Clin.) cure percentages for the following mastitis etiologies on aerobic culture: Escherichia 
coli, Klebsiella spp., and other, defined as Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella pyogenes, 
Corynebacterium spp., Enterobacter spp., and Enterococcus spp. No significant (Sig) growth and no growth also included. Cows with no growth 
results were not included in bacteriological cure analysis. Error bars indicate 95% CI based on SE of the mean proportion.
Table 3. Parameter estimates, SE, statistics, and odds ratios (OR) for fixed effects of a mixed logistic regression model evaluating bacteriological 
cure = true1 (n = 353)
Parameter  Description Estimate SE P-value OR 95% CI
Intercept  0.79 0.28 0.037   
Treatment Hetacillin −0.25 0.26 0.32 0.78 0.47–1.3
 Ceftiofur Referent     
Etiology Streptococcus uberis 0.28 0.42 0.50 1.3 0.58–3.0
 Streptococcus spp. 0.0065 0.48 0.99 1.0 0.39–2.6
 Streptococcus dysgalactiae 0.92 0.41 0.024 2.5 1.1–5.6
 Staphyloccus aureus −1.48 0.42 0.0005 0.23 0.10–0.52
 Klebsiella spp. 0.11 0.48 0.82 1.1 0.44–2.9
 Escherichia coli 1.4 0.45 0.0023 4.0 1.6–9.7
 Other2 Referent     
1Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis event, etiology, and linear score and milk produc-
tion at test day previous to event. Farm was included as a random effect but had no contribution to variance.
2Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella pyogenes, 
Corynebacterium spp., Enterobacter spp., and Enterococcus spp.
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Extended Clinical Cure and Clinical Days
Using resample CS at d 14 ± 4 and 21 ± 5 (n = 
520), bivariate analysis shows 92% (n = 221/241) of 
hetacillin-treated cows with clinical cure and 91% (n 
= 253/279) of ceftiofur-treated cows with clinical cure. 
A Chi-squared comparison indicates no differences 
between treatment groups (P = 0.68). Noninferiority 
Figure 3. Representation of outcome probability differences for hetacillin versus ceftiofur in a noninferiority comparison. The gray boxes 
represent the point estimates for each difference. Arrowheads indicate a 95% CI. Shaded area is representative of noninferiority. Intervals falling 
in the area >0 conclude superiority of hetacillin to ceftiofur. Values crossing −0.15 (the noninferiority margin) are inconclusive. Overall bacte-
riological cure = all etiologies. Pathogen cure (Pcure) is defined as absence of a pathogen on both follow-up samples (d 14 and 21).
Table 4. Parameter estimates, SE, statistics, and odds ratios (OR) for fixed effects of a mixed logistic regression model evaluating pathogen 
cure = true1 (n = 462)
Parameter  Description Estimate SE P-value OR 95% CI
Intercept  1.5 0.61 0.054   
Treatment Hetacillin 0.12 0.21 0.57 1.1 0.75–1.7
 Ceftiofur Referent     
Milk2  −0.027 0.011 0.014 0.97 0.95–1.0
Linear score3  −0.10 0.05 0.037 0.90 0.82–0.99
Etiology Streptococcus uberis −0.80 0.40 0.047 0.46 0.20–1.0
 Streptococcus spp. −1.76 0.54 0.0011 0.18 0.063–0.51
 Streptococcus dysgalactiae −0.75 0.33 0.026 0.49 0.25–0.94
 Staphylococcus aureus −2.37 0.55 <0.0001 0.094 0.032–0.28
 Klebsiella spp. −0.86 0.48 0.075 0.44 0.17–1.1
 Escherichia coli 0.029 0.34 0.93 1.1 0.54–2.1
 Other4 −0.61 0.33 0.066 0.56 0.29–1.1
 No growth Referent     
1Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis event, etiology, and linear score and milk produc-
tion at test day previous to event. Farm was included as a random effect.
2Milk production (kg) on test d 8 to 43 d before clinical mastitis event.
3Linear score on test d 8 to 43 d before clinical mastitis event.
4Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella pyogenes, 
Corynebacterium spp., Enterobacter spp., and Enterococcus spp.
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analysis confirms that the treatments are noninferior 
when assessing this outcome (risk difference = 0.010, 
95% CI: −0.039–0.059).
Any cow experiencing 5 or more clinical days was 
given a value of 5. Bivariate analysis indicated a dif-
ference in clinical days between treatment groups (P 
= 0.0026), with the hetacillin-treated cows experienc-
ing overall less days (3.4 d; 95% CI: 1.3–1.5) versus 
ceftiofur-treated cows (3.7 d; 95% CI: 1.3–1.5). Lack of 
normality of clinical days did not permit linear regres-
sion modeling.
Postevent Milk Yield
All cows with milk yield values at 8 to 43 d post-
mastitis event were included in the analysis. The mean 
number of days between mastitis event and test date 
for data retrieval was 23.6 d with a median of 24 d. 
The total number of included cows was 542, with 261 
in the hetacillin group and 281 in the ceftiofur group. 
Average postevent milk yield between the groups was 
similar; the average test-day milk for hetacillin-treated 
cows was 38.2 kg whereas the average milk for ceftiofur-
treated cows was 38.7 kg (bivariate analysis, P = 0.54). 
A mixed linear regression model used 484 observa-
tions and included DIM category, previous test-day 
milk yield, and etiology. The least squares means for 
hetacillin-treated and ceftiofur-treated cows were 37.0 
and 38.2 kg, respectively (P = 0.09). In the model, as 
expected, as previous milk yield increased, postevent 
milk yield increased. Cows lower in DIM had signifi-
cantly greater milk production than those >200 DIM, 
and the least squares means for milk yield decreased 
with increasing DIM category. All etiology groups had 
lower milk production than those with no growth re-
sults (Table 5).
Postevent LS
All cows with LS values at 8 to 43 d postmastitis 
event were assessed for analysis (n = 531; hetacillin 
= 251, ceftiofur = 280). The mean number of days 
between mastitis event and test date for data retrieval 
was 23.6 d with a median of 24 d. Average postevent LS 
for hetacillin-treated cows and ceftiofur-treated cows 
were 3.4 and 3.1, respectively (bivariate analysis, P = 
0.66). A mixed linear regression model included previ-
ous LS, parity, and etiology. The least squares means 
for hetacillin-treated and ceftiofur-treated cows were 
3.4 and 3.1, respectively (P = 0.086). A total of 466 
cows were included in the model. As expected, previ-
ous LS was significant in the model; as previous LS 
increased, postevent LS increased. In the model, each 
earlier parity had a lower LS than the third and greater 
parity when other variables were accounted for (P = 
0.0032). All culture results had higher LS than those 
cows culturing with no growth results. P-values and 
least squares means for each etiology can be found in 
Table 6.
Survival to d 30
A cow not surviving was defined as having experi-
enced culling or death. A total of 585 cows were in-
cluded in the analysis: 284 hetacillin-treated cows and 
301 ceftiofur-treated cows. Overall, 95% of cows sur-
Table 5. Parameter estimates, SE, statistics, and LSM for fixed effects of a mixed linear regression model evaluating postevent milk production 
(kg)1 (n = 484)
Parameter  Description Estimate SE P-value LSM (kg) 95% CI
Intercept  11.3 1.7 0.0011   
Treatment Hetacillin −1.2 0.68 0.091 37.0 35.9–38.2
 Ceftiofur Referent   38.2 37.1–39.3
Previous milk2 (kg)  0.56 0.035 <0.0001   
Days in milk 1–100 10.2 0.92 <0.0001 43.0 41.8–44.3
 101–200 4.2 0.89 <0.0001 37.0 35.8–38.2
 >200 Referent   32.8 31.3–34.3
Etiology Streptococcus uberis −1.7 1.4 0.20 37.9 35.5–40.4
 Streptococcus spp. −0.85 1.6 0.59 38.8 35.9–41.7
 Streptococcus dysgalactiae −3.2 1.1 0.0033 36.5 34.6–38.3
 Staphylococcus aureus −1.8 1.4 0.18 37.8 35.4–40.3
 Klebsiella spp. −1.4 1.6 0.39 38.3 35.4–41.2
 Escherichia coli −4.2 1.1 0.0002 35.4 33.6–37.3
 Other3 −3.3 1.1 0.0026 36.4 34.5–38.2
 No growth Referent   39.7 38.4–40.9
1Within 8 to 43 d postevent. Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis event, etiology, and 
linear score and milk production at test day previous to event. Farm was included as a random effect.
2Milk production (kg) at previous test-date (8–43 d premastitis event).
3Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella pyogenes, 
Corynebacterium spp., Enterobacter spp., and Enterococcus spp.
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vived to d 30. Of the hetacillin-treated cows, 12 (4.2%) 
did not survive to 30 d compared with 15 (5.0%) of 
ceftiofur-treated cows. In a mixed logistic regression 
model with 521 observations, the odds of survival were 
higher in the hetacillin group (OR = 1.2), but treat-
ment group was not statistically significant (P = 0.73). 
The only significant variable was previous milk yield (P 
= 0.022), which showed an increased odds of survival 
with increasing previous milk yield (OR = 1.05; 95% 
CI: 1.01–1.1). Noninferiority analysis resulted in a risk 
difference of 0.0076 (95% CI: −0.026–0.042; Figure 3).
Survival to d 60
The same cow inclusions were made as for survival 
to d 30 (n = 585; hetacillin = 284; ceftiofur = 301). 
Overall, 91% of cows survived to d 60. Of the hetacillin-
treated cows, 22 (7.8%) did not survive to 60 d com-
pared with 30 (10.0%) of the ceftiofur-treated cows. In 
a mixed logistic regression model, the odds of survival 
were higher in the hetacillin group (OR = 1.4) but the 
P-value was 0.26. In the model, the odds of survival 
increased as previous milk yield increased (OR = 1.04; 
95% CI: 1.01–1.07; P = 0.012). The risk difference was 
0.022 (95% CI: −0.024–0.068; Figure 3).
Time-to-Event: Survival Analysis  
and Mastitis Recurrence
The same cows included in logistic analysis of 
survival to 30 and 60 d were included in the time-to-
event analysis for overall survival (n = 585; hetacillin 
= 284; ceftiofur = 301). A total of 521 observations 
were included in Cox proportional hazards regression. 
Modeling for overall survival in time-to-event analysis 
provided a hazard ratio of 0.74 when comparing het-
acillin- to ceftiofur-treated cows, indicating a reduction 
in risk of 26% for that group. The treatment group 
P-value was 0.27. The only variables that remained in 
the model were parity (P = 0.086) and previous milk 
yield (P = 0.0010).
Modeling for time-to-mastitis event in the same quar-
ter provided a hazard ratio for the hetacillin group over 
the ceftiofur group of 1.1 (P = 0.73) when controlling 
for milk yield. One farm did not reliably record mastitis 
at the quarter level, leading to removal of 104 cows 
from analysis. Three cows were not included because 
their quarter ceased production within 7 d of enroll-
ment. The total number of cows eligible for analysis 
was 478 (hetacillin = 229; ceftiofur = 249). A total of 
421 observations were included in a Cox proportional 
hazards regression model. Only previous milk yield was 
significant in the model (P = 0.0004).
Hospital Days
A cow was eligible for hospital days analysis when a 
pen move occurred, indicating exit from the treatment 
pen in both DC305 and the written record (n = 351). 
Four of 6 of the dairies reliably recorded pen moves; 
cows enrolled from 2 of the dairies did not contribute 
to analysis of this outcome. The number of cows meet-
ing criteria was 344 (hetacillin = 164; ceftiofur = 180). 
Data were normalized using the log of hospital days 
Table 6. Parameter estimates, SE, statistics, and LSM for fixed effects of a mixed linear regression model evaluating postevent linear score 
(LS)1 (n = 466)
Parameter  Description Estimate SE P-value LSM 95% CI
Intercept  2.41 0.28 0.0004   
Treatment Hetacillin 0.36 0.21 0.086 3.4 3.0–3.8
 Ceftiofur Referent   3.1 2.7–3.5
Previous LS2  0.21 0.049 <0.0001   
Parity 1 −0.85 0.31 0.0064 2.9 2.3–3.5
 2 −0.64 0.23 0.0065 3.1 2.7–3.6
 ≥3 Referent   3.8 3.4–4.1
Etiology Streptococcus uberis 0.92 0.41 0.024 3.5 2.7–4.3
 Streptococcus spp. 0.082 0.48 0.87 2.7 1.7–3.6
 Streptococcus dysgalactiae 0.76 0.33 0.024 3.3 2.8–3.9
 Staphylococcus aureus 1.8 0.44 <0.0001 4.3 3.5–5.1
 Klebsiella spp. 0.69 0.48 0.15 3.3 2.4–4.2
 Escherichia coli 0.60 0.35 0.085 3.2 2.6–3.8
 Other3 0.68 0.33 0.039 3.3 2.7–3.8
 No growth Referent   2.6 2.1–3.0
1Within 8 to 43 d postevent. Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis event, etiology and 
LS and milk production at test day previous to event. Farm was included as a random effect.
2Linear score at previous test-date (8–43 d premastitis event).
3Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella pyogenes, 
Corynebacterium spp., Enterobacter spp., and Enterococcus spp.
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as the outcome. Bivariate analysis revealed a greater 
number of hospital days for the ceftiofur-treated group 
(8.0 d) versus the hetacillin-treated group (6.2 d; P 
< 0.001). A mixed linear regression model included 
etiology as the only significant covariate, but values for 
least squares means remained constant (ceftiofur = 8.0 
d, hetacillin = 6.2 d; P < 0.001). Table 7 describes the 
model of log of hospital days. On average, all etiologies 
aside from Klebsiella spp. and other experienced more 
hospital days than no growth cows. Using no growth 
as the base in the model, only Staph. aureus differed 
statistically in hospital days.
DISCUSSION
Using a noninferiority comparison, our study evalu-
ated the efficacy of 2 IMM antibiotic preparations 
for the treatment of mild to moderate CM. The most 
important findings are summarized in Figure 3; the 
current study found that hetacillin was noninferior to 
ceftiofur in the primary outcomes of bacteriological, 
pathogen, and clinical cures and secondary outcomes 
describing survival to 30 and 60 d. Hetacillin was supe-
rior to ceftiofur when clinical days was dichotomized to 
less than or equal to 4 d.
The overall bacteriological cure risk difference be-
tween the groups was −0.047. Noninferiority could be 
stated when the 95% confidence interval (−0.143 to 
0.048) falls above the noninferiority margin of −0.15. 
When comparing gram-positive to -negative etiologies, 
a larger risk difference than for an overall comparison 
was seen in CM caused by gram-positive organisms. 
Upon further examination of the risk difference for 
gram-positive etiologies, it was noted that although nu-
merically higher cure rates were observed for hetacillin-
treated CNS and hetacillin-treated Staph. aureus cows 
than the respective ceftiofur-treated cows, ceftiofur 
had higher cure rates in the more represented culture 
outcomes such as Strep. dysgalactiae (Figure 1). The 
bacteriological cure risk difference was lowest (least 
negative) for gram-negative etiologies, resulting from 
a numerically higher but nonsignificant cure rate for 
ceftiofur-treated E. coli and Klebsiella cows versus the 
respective hetacillin-treated cows. The confidence inter-
vals of the risk differences for gram-positive and -nega-
tive etiologies cross both the noninferiority limit and 
zero, suggesting that we lacked the power to identify an 
observed difference smaller than our declared margin. 
This may have been due to the smaller sample size 
when culture results were separated by gram-negative 
and gram-positive status.
Despite the large difference seen in bacteriological 
cure of Strep. dysgalactiae CM between hetacillin- and 
ceftiofur-treated cows (ceftiofur having a greater cure), 
the rate of clinical cure by d 4 for this organism was 
greater for hetacillin-treated cows. The same could be 
seen for the gram-negative organisms, E. coli and Kleb-
siella spp.; despite a numerically greater bacteriological 
cure for ceftiofur, this drug had a lower percentage of 
clinical cures for these organisms as compared with 
hetacillin. Analysis of the binary outcome “clinical 
cure in less than 4 days” resulted in a positive risk 
difference of 0.119; a confidence interval beyond both 
the noninferiority limit, −0.15, and zero indicates su-
periority of hetacillin over ceftiofur for this outcome 
(Figure 3). One could speculate that clinical cure rates 
may be higher for hetacillin cows due to bias; CS is a 
subjective measure and having to treat ceftiofur cows 2 
additional days may have led observers to be more criti-
cal of symptoms before administration of medication. 
Blinding in regard to treatment was not performed in 
our trial, but producers and researchers were unaware 
Table 7. Parameter estimates, SE, statistics, and LSM of a mixed linear regression model evaluating log(hospital days)1 (n = 344)
Parameter  Description Estimate SE P-value LSM (d) 95% CI
Intercept   2.0 0.14 0.0007    
Treatment Hetacillin −0.26 0.03 <0.0001 6.2 4.7–8.1
  Ceftiofur Referent     8.0 6.1–10.4
Etiology Streptococcus uberis 0.05 0.08 0.50 7.0 5.1–9.4
  Streptococcus spp. 0.11 0.072 0.11 7.4 5.6–10.0
  Streptococcus dysgalactiae 0.087 0.058 0.14 7.23 5.5–9.6
  Staphylococcus aureus 0.22 0.062 0.0004 8.3 6.2–11.0
  Klebsiella spp. −0.055 0.068 0.42 6.3 4.7–8.4
  Escherichia coli 0.017 0.050 0.74 6.8 5.2–8.9
  Other2 −0.0025 0.054 0.96 6.6 5.0–8.7
  No growth Referent     6.6 5.1–8.7
1Parameters evaluated for potential confounding included cow parity, DIM at clinical mastitis event, etiology, and linear score and milk produc-
tion at test day previous to event. Farm was included as a random effect.
2Included nonsignificant growth, Pseudomonas spp., Proteus spp., gram-negative bacillus, yeast, Prototheca spp., Trueperella pyogenes, 
Corynebacterium spp., Enterobacter spp., and Enterococcus spp.
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of objective primary outcomes, including bacteriologic 
and pathogen cures and the quantitative secondary 
outcomes LS and milk production.
To obtain the power and numbers needed to evaluate 
CM treatment efficacy, trials that use bacteriological 
cure as a primary outcome must restrict treatment as-
signment to cases in which bacteria are isolated. This 
then determines the need to wait for culture results be-
fore administration of the product (Schukken and De-
luyker, 1995). In the current study, we used a pathogen 
cure outcome, following and modifying the ideas out-
lined in Pinzón-Sanchez and Ruegg (2011) and Oliveira 
et al. (2013), to facilitate the inclusion of no growth 
results. This allows researchers to analyze the risk of 
remaining pathogen free. Our values of 43 and 45% for 
pathogen cure of ceftiofur- and hetacillin-treated cows, 
respectively, were lower than the 65% (n = 276/427) 
found by Oliveira et al. (2013; IMM treatment with any 
antimicrobial). Low values for pathogen cure may be 
due to the large number (~25%) of Streptococcus spp.-
positive cows in the trial. Whereas the cure rate for 
CM caused by environmental streptococci may exceed 
50%, cows can suffer frequent relapses (Guterbock et 
al., 1993; Van Eenennaam et al., 1995; Morin et al., 
1998). The delay of treatment may have affected these 
cows, as aggressive IMM treatment of Strep. uberis CM 
has been shown to result in cure rates that exceed 90% 
(Hillerton and Kliem, 2002).
Our average clinical days, 3.4 and 3.7 for hetacil-
lin- and ceftiofur-treated cows, respectively, are lower 
than the ceftiofur-treated cows (4.5 d, n = 262) and 
cephapirin-treated cows (4.9 d, n = 49) in a CM study 
performed by Oliveira and Ruegg (2014). Our results 
were also less than cephalosporin treated cows in an 
earlier study by Pinzón-Sanchez and Ruegg (2011; 5.4 
d, n = 143). This is likely due to our assignment of 5 
clinical days to those cows that exhibited clinical signs 
beyond the initial observation period. An additional 
study detected lower values than found in the present 
study for clinical days, at 2.7 and 3.2 d for blanket-
treated cephapirin and selectively treated cephapirin 
cows, respectively (Lago et al., 2011a). Despite these 
deviations from our findings, each study referenced 
concluded no statistical differences between treatment 
groups in days to clinical cure.
For extended clinical outcome comparisons, 92% of 
hetacillin-treated cows and 91% of ceftiofur-treated 
cows retained their cured statuses on d 14 and 21 
postenrollment. This differs from the Schukken et al. 
(2013) study that found an overall clinical cure of 62% 
(n = 184/296) at d 10 and 17. This may be due to the 
clinical scoring system in their study, which included 
rectal temperature, hydration scoring, and attitude as-
sessment.
The model for postevent milk production included 
etiology as a significant variable. When the causative 
microorganism was absent on initial culture (a no growth 
result), cows responded with a significantly higher milk 
production than those with growth. Mastitis is associ-
ated with losses in milk production, particularly for 
coliform cases (Grऺhn et al., 2004). Our data indicates 
that cows with E. coli average the greatest loss in milk 
production at next test day relative to other etiologies. 
Values were similar to a change of −4.62 kg found by 
Grऺhn et al. (2004) for cows 15 to 21 DIM. In the 
latter study, however, Klebsiella affected cows suffered 
the greatest loss, with an average change of −6.24 kg 
of milk/d during this time period. Our differences may 
be reflective of the few numbers of Klebsiella cases or 
the various genetic strains found on 6 dairies (Grऺhn 
et al., 2004).
Parity, previous LS, and etiology were significant in 
a model for postevent LS. Inclusion of these variables 
agreed with known risk factors associated with short-
term posttreatment outcomes (Pinzón-Sanchez and 
Ruegg, 2011). In regard to etiology, Staph. aureus cows 
experienced the highest postevent LS. This is supported 
by the fact that Staph. aureus is commonly cultured 
in dairies with high bulk tank SCC (Barkema et al., 
1997). Treatment was not significant in the model. No 
comparisons have been described in recent literature 
between hetacillin and ceftiofur for posttreatment milk 
quality and quantity indices. However, Schukken et 
al. (2011) concluded no significant differences in SCC 
nor milk yield for the remainder of the lactation when 
considering ceftiofur-treated gram-negative cases and 
untreated gram-negative cases.
Noninferiority was described for hetacillin in both 
survival indices (Figure 3). Historically, the culling 
rate for CM cows was estimated to be more than twice 
that of non-CM cows; the risk of culling is highest in 
the period immediate to the mastitis event (Barkema 
et al., 1997; Grऺhn et al., 2004). For this reason, we 
used a 60-d interval for event analysis, but expected 
to find similar results had we followed the cows for 
a longer period of time. Though this is the first trial 
comparing IMM hetacillin to ceftiofur, recent selective 
treatment trials have reported no statistical differences 
in removal from the herd within the weeks after CM 
when cows were treated with different cephalosporin 
products or protocols (Lago et al., 2011a,b). The costs 
of culling contribute to the total costs of CM and also 
influence the benefits returned from intensive antimi-
crobial treatments; knowledge of noninferiority of one 
product to another for survival indices is economically 
important (Steeneveld et al., 2011).
Milk yield was similarly significant in Cox propor-
tional hazards analysis when assessing survival in the 
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herd and time-to-next-mastitis in the same quarter. 
However, the recurrence risk of CM was not dependent 
on etiology in our analysis. Whereas this model agreed 
with a previous study performed by Lago et al. (2011b) 
in which the effect of organism was not significant, eti-
ology was a sensitive indicator for recurrence risk in a 
streptococcal CM study (Van Eenennaam et al., 1995). 
The uneven distribution of Strep. uberis may have pre-
cluded the detection of an effect of etiology in survival 
analysis. Additionally, the larger percentage of these 
cows in the ceftiofur-treated group may introduce bias 
when assessing etiological analysis for each of the treat-
ment outcomes, particularly if ceftiofur cows generally 
experience higher cure rates for this etiology.
The only significant difference between treatment 
groups was for hospital days, with a difference in least 
squares means of 1.8 d, favoring hetacillin. This differ-
ence results from 2 less treatment days for hetacillin 
cows while maintaining the same 72-h milk withhold for 
each product. Within the design of the study, although 
milk withhold times were the same, treatment duration 
protocols for the drugs were not identical. Based on a 
recent Wisconsin study, which characterized an average 
duration for IMM ceftiofur use between 4 and 5 d, 5 d 
was selected for treatment length in this trial (Oliveira 
and Ruegg, 2014). We felt that selection of this dura-
tion (1) reflected current farm use and (2) permitted 
ceftiofur the best chance to display better efficacy over 
hetacillin. The hetacillin label indication dictated the 
3-d treatment period for this drug. Although the differ-
ence may be evident to readers, as producers are sim-
ply following the pasteurized milk ordinance, we were 
unable to assume that hetacillin- nor ceftiofur-treated 
cows would experience unresolved clinical signs beyond 
the withhold date without actually testing it. Cows in 
the study remained in the hospital pen until their milk 
was no longer violative and symptoms of CM were re-
solved. Initial study design considered that clinical days 
may have been a more important factor in hospital day 
analysis than both the withhold and treatment dura-
tions. An economic analysis for hetacillin treatment in 
regards to decreased labor costs and increased days of 
saleable milk was not performed.
When assessing severity of CM, approximately 14% 
of cows did not qualify due to systemic signs. This 
was similar to the 15.3% value found in a survey of 
50 Wisconsin dairy farms (Oliveira et al., 2013), but 
higher than values found on a smaller survey (8%, n = 
266) and in a recent Canadian survey (10%, n = 2,311; 
Olde Riekerink et al., 2008; Pinzón-Sanchez and Ruegg, 
2011). Exclusion of severe CM cows limits the general-
izability of our results to cows with nonsevere mastitis. 
Due to individualized farm-specific treatment for severe 
mastitis, additional trials would need to be performed 
to assess differences in the 2 antibiotic products.
CONCLUSIONS
A CM trial comparing a 5-d treatment with ceftiofur 
to a 3-d treatment with hetacillin showed noninferiority 
of the latter in regards to bacteriological cure, clinical 
cure, pathogen cure, and survival to 30 and 60 d. When 
noninferiority analysis was applied to gram-positive 
and -negative etiological groups, the data were incon-
clusive. However, results are consistent with the fact 
that these 2 IMM products are effective against 1 or 
more gram-positive organisms as well as gram-negative 
E. coli. No statistically significant differences in con-
tinuous outcomes such as clinical days, postevent milk 
yields, and postevent LS were found between treatment 
groups. Hospital days differed favorably for hetacillin 
versus ceftiofur, allowing milk from hetacillin-treated 
cows to contribute to the bulk tank 1.8 d earlier than 
the respective ceftiofur-treated cows. No effect of treat-
ment was observed on risk of leaving the herd in 60 d 
or on risk of experiencing a new mastitis event in the 
same quarter. Differences in bacteriological cure pro-
files, however, determine the importance of pretreat-
ment diagnostics. Farms with access to culture results 
may benefit most from our results. Our findings can 
aid in herd-specific decisions, specifically in developing 
treatment protocols for nonsevere CM.
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